Biological Activity
6-Hydroxy-DOPA is a selective and effective allosteric inhibitor of the RAD52 ssDNA binding domain. 6-Hydroxy-DOPA can be used for the research of cancer[1].
In Vitro
6-Hydroxy-DOPA (0~20 μM; U20S cells) selectively inhibits RAD52-mediated recombination. 6-Hydroxy-DOPA (0~10 μM; HEK293T cells) decreases the number of eGFP-RAD52 foci in a dose-dependent manner. 6-Hydroxy-DOPA (5~75 μM; HCC1937 cells) selectively reduces the viability of the BRCA1-deficient triple-negative breast cancer cell line HCC1937[1].
In Vivo
No in vivo data are provided in the current product source. Contact us for further information.
Target
RAD52[1]
References & source
[1]. Chandramouly G, et al. Small-Molecule Disruption of RAD52 Rings as a Mechanism for Precision Medicine in BRCA-Deficient Cancers. Chem Biol. 2015;22(11):1491-1504.
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.
